Moorfields Clinical Research Facility
Since 2017, the NIHR Moorfields Clinical Research Facility (CRF) has pioneered the translation of laboratory discoveries for the benefit of patients with eye conditions and the NHS. This includes:
• The first gene therapy trial to cure, Leber's congenital amaurosis (LCA), a rare inherited eye disease
• The first stem cell membrane therapy trial to treat age-related macular degeneration (AMD)
These advances have cemented the Moorfields CRF’s international reputation for experimental eye treatments and attracted industry investment, underpinned by funding from the NIHR.
What is the Moorfields CRF?
The Moorfields CRF contains 26 patient examination rooms with associated research and treatment units, and is designed to test new methods of diagnosing common and rare eye diseases, as well as evaluate innovative treatments for them.
The CRF is part of the internationally renowned partnership between Moorfields Eye Hospital and the UCL Institute of Ophthalmology in London that includes the NIHR Moorfields Biomedical Research Centre.
Who funds the Moorfields CRF?
In 2017, Moorfields Eye Hospital NHS Foundation Trust received a five-year funding award of £5.3 million for clinical research from the National Institute for Health and Care Research (NIHR), recognising our centre's world-leading excellence in this area.
A short video about the Moorfields CRF